Current strategies in the treatment of non-muscle-invasive bladder cancer

Abstract

This review is based on a data search up to the end of January 2012 on strategies in the treatment of non-muscle-invasive bladder cancer. One of the authors was chairman of the guidelines writing committee of the European Association of Urology, and these guidelines served as a backbone. They are updated and adapted according to the most recent data. It is astonishing how much important data were published in the last 2 years. Many data have a high level of evidence and allow well-supported recommendations. However, recommendations are not given but the discussion for reflection on it is given in this article.

Keywords::

• bacillus Calmette–Guérin
• epirubicine
• mitomycine C
• non-muscle-invasive bladder cancer
• review
• urothelial neoplasm

Financial & competing interests disclosure

W Oosterlinck was a speaker on several occasions for Kyowa (Mitomycin) and General Electric (Hexvix). The authors have no other relevant affiliations or financial involvement with any organization or entity with a financial interest in or financial conflict with the subject matter or materials discussed in the manuscript apart from those disclosed.

No writing assistance was utilized in the production of this manuscript.